Imricor Medical Systems (ASX:IMR) fell past 4% in Friday trade, a "complete overreaction", after the company reported a delay in US regulatory progress, despite positive developments in Europe, according to a Thursday note by Morgans Financials.
On Wednesday, the company said it received European medical device regulation approval for its products, including its NorthStar mapping system, ablation catheter, and capital equipment.
The company added that the US Food and Drug Administration has reassigned the reviewer for its second Premarket Approval (PMA) module, which covers only the ablation catheter and RF generator.
However, the company said it does not expect the PMA delay to materially impact its commercial trajectory.
Morgans said the company has several upcoming catalysts over the next few quarters, including expected US approval of NorthStar, which will drive the share price.
Morgans Financial maintained Imricor's speculative buy rating.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。